CN118141810A - 用于治疗性治疗的包含加波沙朵的药物制剂 - Google Patents

用于治疗性治疗的包含加波沙朵的药物制剂 Download PDF

Info

Publication number
CN118141810A
CN118141810A CN202410172907.XA CN202410172907A CN118141810A CN 118141810 A CN118141810 A CN 118141810A CN 202410172907 A CN202410172907 A CN 202410172907A CN 118141810 A CN118141810 A CN 118141810A
Authority
CN
China
Prior art keywords
gaboxadol
pharmaceutically acceptable
acceptable salt
drug
release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202410172907.XA
Other languages
English (en)
Chinese (zh)
Inventor
马修·杜林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ovid Therapeutics Inc
Original Assignee
Ovid Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ovid Therapeutics Inc filed Critical Ovid Therapeutics Inc
Publication of CN118141810A publication Critical patent/CN118141810A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202410172907.XA 2019-07-15 2020-07-15 用于治疗性治疗的包含加波沙朵的药物制剂 Pending CN118141810A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962874152P 2019-07-15 2019-07-15
US62/874,152 2019-07-15
PCT/US2020/042044 WO2021011597A1 (en) 2019-07-15 2020-07-15 Pharmaceutical formulations containing gaboxadol for therapeutic treatment
CN202080051393.2A CN114173765A (zh) 2019-07-15 2020-07-15 用于治疗性治疗的包含加波沙朵的药物制剂

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202080051393.2A Division CN114173765A (zh) 2019-07-15 2020-07-15 用于治疗性治疗的包含加波沙朵的药物制剂

Publications (1)

Publication Number Publication Date
CN118141810A true CN118141810A (zh) 2024-06-07

Family

ID=74211193

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202410172907.XA Pending CN118141810A (zh) 2019-07-15 2020-07-15 用于治疗性治疗的包含加波沙朵的药物制剂
CN202080051393.2A Pending CN114173765A (zh) 2019-07-15 2020-07-15 用于治疗性治疗的包含加波沙朵的药物制剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202080051393.2A Pending CN114173765A (zh) 2019-07-15 2020-07-15 用于治疗性治疗的包含加波沙朵的药物制剂

Country Status (10)

Country Link
US (3) US20210015760A1 (enExample)
EP (1) EP3982937A4 (enExample)
JP (1) JP2022540917A (enExample)
KR (1) KR20220035195A (enExample)
CN (2) CN118141810A (enExample)
AU (1) AU2020313930A1 (enExample)
CA (1) CA3146737A1 (enExample)
IL (1) IL289657A (enExample)
MX (1) MX2022000663A (enExample)
WO (1) WO2021011597A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180338959A1 (en) * 2017-05-24 2018-11-29 Ovid Therapeutics Inc. Treatment of depressive disorders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3795156A1 (en) * 2014-06-06 2021-03-24 Ovid Therapeutics, Inc. Pharmaceutical composition for treating angelman syndrome
EP3154979B1 (en) * 2014-06-12 2018-03-07 Pfizer Limited Imidazopyridazine derivatives as modulators of the gabaa receptor activity.
CN108024997A (zh) * 2015-07-17 2018-05-11 奥维德医疗公司 用加波沙朵治疗发育障碍的方法
US20170348232A1 (en) * 2016-06-07 2017-12-07 Ovid Therapeutics Inc. Formulations of gaboxadol for treatment of angelman syndrome, fragile x syndrome and fragile x-associated tremor/ataxia syndrome
KR20230050474A (ko) * 2016-08-11 2023-04-14 오비드 테라퓨틱스 인크. 간질 장애의 치료를 위한 방법 및 조성물
EP3528807A4 (en) * 2016-11-22 2020-06-17 Ovid Therapeutics Inc METHOD FOR TREATING DEVELOPMENT DISORDERS AND / OR FALLS WITH FLUPIRTIN

Also Published As

Publication number Publication date
US20210015760A1 (en) 2021-01-21
IL289657A (en) 2022-03-01
EP3982937A1 (en) 2022-04-20
KR20220035195A (ko) 2022-03-21
CA3146737A1 (en) 2021-01-21
AU2020313930A1 (en) 2022-02-03
MX2022000663A (es) 2022-02-16
US20240252447A1 (en) 2024-08-01
EP3982937A4 (en) 2022-08-10
US20220040120A1 (en) 2022-02-10
JP2022540917A (ja) 2022-09-20
CN114173765A (zh) 2022-03-11
WO2021011597A1 (en) 2021-01-21

Similar Documents

Publication Publication Date Title
EP2688557B1 (en) Methods and compositions for treatment of attention deficit disorder
Narang et al. Sublingual mucosa as a route for systemic drug delivery
JPH11511162A (ja) ドーパミン作用物質のための経口速溶性組成物
EA013744B1 (ru) Фармацевтические композиции на основе нейроактивного стероида и их применение
JP2011515485A (ja) ロフェキシジンを経粘膜送達するための組成物およびその方法
US20200222372A1 (en) Use of gaboxadol in the treatment of narcolepsy
JP2008540437A (ja) キニーネを含有する制御放出調合剤
US20240252447A1 (en) Pharmaceutical formulations containing gaboxadol for therapeutic treatment
US11364228B2 (en) Gaboxadol for therapeutic treatment of 1p36 deletion syndrome
JP2024507264A (ja) メラトニンを含む多層ペレットの製剤
KR101473998B1 (ko) 에페리손 함유 필름코팅정제
KR101565505B1 (ko) 에페리손을 함유하는 새로운 약물 전달 시스템
HK40073671B (en) Methods and compositions for treatment of attention deficit disorder
CN113423399A (zh) 加波沙朵用于治疗非24小时睡眠-觉醒障碍的用途
HK40031715A (en) Use of gaboxadol in the treatment of narcolepsy

Legal Events

Date Code Title Description
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination